NASDAQ:VRAYViewray Stock Price, Forecast & News

Viewray's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 38.5% and is now trading at $2.34. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray.

Viewray is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Viewray.

Viewray Inc (NASDAQ:VRAY) issued its quarterly earnings results on Thursday, April, 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.19). The company had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.47 million. Viewray had a negative return on equity of 71.37% and a negative net margin of 139.91%. View Viewray's earnings history.

10 brokers have issued 12-month price objectives for Viewray's shares. Their forecasts range from $2.00 to $8.00. On average, they expect Viewray's share price to reach $4.83 in the next twelve months. This suggests a possible upside of 106.6% from the stock's current price. View analysts' price targets for Viewray.

News coverage about VRAY stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Viewray earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Viewray.

Some companies that are related to Viewray include InMode (INMD), Zynex (ZYXI), Natus Medical (NTUS), BioLife Solutions (BLFS), AxoGen (AXGN), TransMedics Group (TMDX), Stereotaxis (STXS), Semler Scientific (SMLR), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), Fc Global Realty (FCRE) and electroCore (ECOR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $2.34.

Viewray has a market capitalization of $344.91 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The official website for Viewray is www.viewray.com.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]